Phase 3 ePHex Study: OxThera Reports Results
Sid Martin Biotech alum OxThera AB, a biopharma company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces results of its pivotal Phase 3 study.
New OxThera/Oxabact US Patent Granted
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces that a new US patent has been granted for its product candidate Oxabact and a method for the treatment or prevention of an oxalate-related disorder, such as hyperoxaluria.
Plasma Oxalate and Kidney Function Are Correlated in Patients With Primary Hyperoxaluria With Maintained Kidney Function – Data From Three Placebo-Controlled Studies Published
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.
OxThera Announces Completion of Recruitment in Phase 3 ePHex Study With Oxabact in Patients With Primary Hyperoxaluria
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced that it... Read More
OxThera Presents Full 24-Month Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients With ESRD
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), presented data from... Read More
OxThera Receives Positive Decision From EMA on Paediatric Investigational Plan (PIP) for Treatment of Primary Hyperoxaluria With Oxalobacter Formigenes
UF startup OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announced that, based... Read More
Oxthera Presents Continuous Strong Data from an Interim Analysis of Its Phase 2 Study with Oxabact in Primary Hyperoxaluria
UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company dedicated to improving the lives of people living with Primary Hyperoxaluria (PH), announced... Read More
OxThera Initiates Extension Part of a Phase 3 Study of Oxabact in Primary Hyperoxaluria
UF startup OxThera AB, a privately-held Stockholm-based biopharmaceutical company dedicated to improving the lives of people living with Primary Hyperoxaluria, announced that... Read More
OxThera Presents Encouraging 52-Week Efficacy and Safety Data for Oxabact® in Primary Hyperoxaluria Type 1 (PH1) Patients with ESRD (PR Newswire)
UF startup OxThera AB, a Stockholm-based privately-held biopharmaceutical company and leader in the field of microbiome derived biotherapeutics, announced a poster presentation... Read More
